Company news

Royalty Pharma plc news in 2023

Royalty Pharma plc's news releases, calls and decks from 2023, newest first.

View company

Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference

November 26, 2023

Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program

November 12, 2023

Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program

November 12, 2023

Royalty Pharma Reports Third Quarter 2023 Results

November 7, 2023

Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi

October 18, 2023

Royalty Pharma Declares Fourth Quarter 2023 Dividend

October 15, 2023

Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023

October 10, 2023

Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

September 20, 2023

Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)

August 23, 2023

Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)

August 23, 2023

Royalty Pharma Reports Second Quarter 2023 Results

August 7, 2023

Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023

July 17, 2023

Royalty Pharma Declares Third Quarter 2023 Dividend

July 16, 2023

Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

June 6, 2023

Royalty Pharma Reports First Quarter 2023 Results

May 8, 2023

Royalty Pharma To Present At The BofA Securities 2023 Health Care Conference

May 2, 2023

Royalty Pharma Declares Second Quarter 2023 Dividend

April 16, 2023

Royalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023

April 12, 2023

Royalty Pharma Announces $1.0 Billion Share Repurchase Program

March 26, 2023

Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million

March 22, 2023

PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million

March 22, 2023

Royalty Pharma Raises Full Year 2023 Guidance

March 14, 2023

Royalty Pharma Appoints Ashwin Pai as Executive Vice President, Investments

February 28, 2023

Royalty Pharma Reports Q4 and Full Year 2022 Results

February 14, 2023

Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023

January 17, 2023

Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference

January 8, 2023

Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness

January 8, 2023

Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness

January 8, 2023

Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 9

January 3, 2023

Calls in 2023

Decks in 2023